11β-hydroxylase deficiency pathophysiology

Jump to navigation Jump to search

Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

11β-hydroxylase deficiency pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 11β-hydroxylase deficiency pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 11β-hydroxylase deficiency pathophysiology

CDC on 11β-hydroxylase deficiency pathophysiology

11β-hydroxylase deficiency pathophysiology in the news

Blogs on 11β-hydroxylase deficiency pathophysiology

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

Risk calculators and risk factors for 11β-hydroxylase deficiency pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Overview

11β-Hydroxylase deficient congenital adrenal hyperplasia (11β-OH CAH) is a type of congenital adrenal hyperplasia (CAH) resulting from a defect in CYP11B1 on chromosome 8. This gene encodes an enzyme called 11β-hydroxylase in the path of steroid biosynthesis. 11β-hydroxylase enzyme is located in the zona fasciculate, and converts 11-deoxycortisol to cortisol and 11-deoxycorticosterone corticosterone. Cortisol production reduction has a negative feedback on the pituitary and increases corticotropin (ACTH) secretion. This leads to of 11-deoxysteroid precursors and then adrenocortical hyperplasia. With intact amount of other pathways, as a result of high ACTH concentrations, some amount of the 11-deoxycortisol precursors are metabolized to adrenal androgens and can cause virilization in a genetically female fetus or a child of either sex. Severity of disease depends on the amount of functional 11-beta-hydroxylase enzyme that an individual produces. Aldosterone production is decreased in this disease but there is an elevation of adrenocorticotropic hormone results in overproduction of 11-deoxycorticosterone (DOC) by mid-childhood. 11-Deoxycorticosterone is a weak mineralocorticoid, but because of high amounts in this disease can cause mineralocorticoid excess effects such as salt retention, volume expansion, and hypertension. Nonclassic forms mostly doesn't have verifiable mutations and mild 11β-hydroxylase deficient is currently considered a very rare cause of hirsutism and infertility.

Pathogenesis

  • 11β-Hydroxylase deficient congenital adrenal hyperplasia (11β-OH CAH) is a type of congenital adrenal hyperplasia (CAH) resulting from a defect in CYP11B1 on chromosome 8.
  • CYP11B1 gene encodes an enzyme called 11β-hydroxylase in the path of steroid biosynthesis. This enzyme is located in the zona fasciculate, and converts 11-deoxycortisol to cortisol and 11-deoxycorticosterone corticosterone.
  • Cortisol production reduction has a negative feedback on the pituitary and increases corticotropin (ACTH) secretion. This leads to of 11-deoxysteroid precursors and then adrenocortical hyperplasia.
  • With intact amount of other pathways, as a result of high ACTH concentrations, some amount of the 11-deoxycortisol precursors are metabolized to adrenal androgens and can cause virilization in a genetically female fetus or a child of either sex.
  • Severity of disease depends on the amount of functional 11-beta-hydroxylase enzyme that an individual produces.
  • Aldosterone production is decreased in this disease but there is an elevation of adrenocorticotropic hormone results in overproduction of 11-deoxycorticosterone (DOC) by mid-childhood. 11-Deoxycorticosterone is a weak mineralocorticoid, but because of high amounts in this disease can cause mineralocorticoid excess effects such as salt retention, volume expansion, and hypertension.
  • Nonclassic forms mostly doesn't have verifiable mutations and mild 11β-hydroxylase deficient is currently considered a very rare cause of hirsutism and infertility.

Genetics

  • 11β-hydroxylase deficiency is an inherited disease with an autosomal recessive pattern, which means both copies of the gene in each cell have gene mutations.
  • Commonly, the parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.
  • Most CYP11B1 mutations correspond to minimal or absent enzyme activity, resulting in the classic congenital adrenal hyperplasia phenotype.
  • A non-classic form of enzyme deficiency caused by CYP11B1 mutations exists but is very rare.[1][2][3]

Associated Conditions

Gross Pathology

On gross pathology the following changes are noted:

  • Thickening of adrenal gland
  • Cerebriform appearance

Microscopic Pathology

On microscopic pathology the following changes are noted:

  • Diffuse cortical hyperplasia
  • Zona reticularis is markedly hyperplastic
  • Lipid depleted cortical cells

References

  1. El-Maouche D, Arlt W, Merke DP (2017). "Congenital adrenal hyperplasia". Lancet. doi:10.1016/S0140-6736(17)31431-9. PMID 28576284.
  2. Zachmann M, Tassinari D, Prader A (1983). "Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients". J. Clin. Endocrinol. Metab. 56 (2): 222–9. doi:10.1210/jcem-56-2-222. PMID 6296182.
  3. Hannah-Shmouni F, Chen W, Merke DP (2017). "Genetics of Congenital Adrenal Hyperplasia". Endocrinol. Metab. Clin. North Am. 46 (2): 435–458. doi:10.1016/j.ecl.2017.01.008. PMID 28476231.